Cargando…

Extended anticoagulation for VTE: what evidence justifies it?

Detalles Bibliográficos
Autores principales:	Walia, Anushka, Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497742/ https://www.ncbi.nlm.nih.gov/pubmed/37711176 http://dx.doi.org/10.3389/fphar.2023.1241979

Ejemplares similares

Multiple myeloma: challenges with deciding the optimal sequencing strategy
por: Walia, Anushka, et al.
Publicado: (2023)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Menstruation, anticoagulation, and contraception: VTE and uterine bleeding
por: Samuelson Bannow, Bethany, et al.
Publicado: (2021)

Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Trial Protocol: A randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study)
por: Tullett, Jayne, et al.
Publicado: (2013)

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

What Justifies Judgments of Inauthenticity?
por: Ahlin, Jesper
Publicado: (2018)

What Are the Conditions That Justify Oöphorectomy?
por: Cushing, Clinton
Publicado: (1883)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

FRI428 VTE And Testosterone Therapy: What Is The Risk?
por: Cheatham, Callie, et al.
Publicado: (2023)

VTE Registry: What Can Be Learned from RIETE?
por: Tzoran, Inna, et al.
Publicado: (2014)

What’s new in VTE risk and prevention in orthopedic surgery
por: Kahn, Susan R., et al.
Publicado: (2020)

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
por: Walia, Anushka, et al.
Publicado: (2023)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Advances in hip arthroplasty surgery: what is justified?
por: Zagra, Luigi
Publicado: (2017)

Risk Assessment for Cancer-Associated VTE: Diversifying the Evidence Base
por: Khorana, Alok A.
Publicado: (2021)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

VTE risk assessment in pregnancy
por: Ewins, Karl, et al.
Publicado: (2019)

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
por: Frere, Corinne, et al.
Publicado: (2020)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Drug Interactions at the Human Placenta: What is the Evidence?
por: Rubinchik-Stern, Miriam, et al.
Publicado: (2012)

COVID-19 and Risk of VTE in Ethnically Diverse Populations
por: Go, Alan S., et al.
Publicado: (2021)

Milan criteria in the MELD era—is it justifiable to extend the limits for orthotopic liver transplantation?
por: Morgul, Mehmet Haluk, et al.
Publicado: (2020)

The concern for developmental neurotoxicology: is it justified and what is being done about it?
por: Tilson, H A
Publicado: (1995)

Commitment to psychiatric care: what justifies broader criteria for minors?
por: Kaltiala-Heino, Riittakerttu, et al.
Publicado: (2007)

Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
por: Amin, A., et al.
Publicado: (2009)

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2016)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Adding pre-emptive anticholinergics to antipsychotics: Is it justified?
por: Chatterjee, Kaushik, et al.
Publicado: (2022)

VTE in ICU Patients With COVID-19
por: Moll, Matthew, et al.
Publicado: (2020)

Metabolomic Profile in Venous Thromboembolism (VTE)
por: Franczyk, Beata, et al.
Publicado: (2021)

CLOTTING AND COVID-19: IT IS NOT ALWAYS VTE
por: LINK, STEPHANIE L, et al.
Publicado: (2022)

Is Gastrostomy Justifiable?
Publicado: (1909)

Justified defection is neither justified nor unjustified in indirect reciprocity
por: Yamamoto, Hitoshi, et al.
Publicado: (2020)

Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.
por: Bradbury, Charlotte, et al.
Publicado: (2019)

Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results
por: Cohen, Alexander T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mmkc4eepotr2d5d7e6beu8hq2m